ADAM17 is associated with EMMPRIN and predicts poor prognosis in patients with uterine cervical carcinoma

Tumor Biology

Volumn 35, Issue 8, 2014, Pages 7575-7586

  Xu, Qin ^a   Ying, Mingang ^a   Chen, Guilin ^a   Lin, Ang ^a   Xie, Yunqing ^a   Ohara, Noriyuki ^b   Zhou, Dongmei ^a  

^a FUJIAN PROVINCIAL CANCER HOSPITAL   (China)

^b Sanda Municipal Hospital   (Japan)

Author keywords

A disintegrin and metalloproteinase 17; Amphiregulin; Cervical carcinoma; Extracellular matrix metalloproteinase inducer; Matrix metalloproteinase; Prognostic biomarker

Indexed keywords

ADAM PROTEIN; AREG PROTEIN, HUMAN; BSG PROTEIN, HUMAN; CD147 ANTIGEN; EPIDERMAL GROWTH FACTOR DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ADULT; AGED; CANCER STAGING; FEMALE; HUMAN; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; UTERINE CERVIX TUMOR;

ADAM PROTEINS; ADULT; AGED; ANTIGENS, CD147; EGF FAMILY OF PROTEINS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; UTERINE CERVICAL NEOPLASMS;

EID: 84922392989     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-1990-1     Document Type: Article

References (44)

1. Rock CL, Michael CW, Reynolds RK, Ruffin MT. Prevention of cervix cancer. Crit Rev Oncol Hematol. 2000;33:169–85.
2. Willmott LJ, Monk BJ. Cervical cancer therapy: current, future and anti-angiogensis targeted treatment. Expert Rev Anticancer Ther. 2009;9(7):895–903.
3. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385:729–33.
4. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature. 1997;385:733–6.
5. Sahin U, Weskamp G, Kelly K, Zhou HM, Higashiyama S, Peschon J, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol. 2004;164:769–79.
6. Gaffney DK, Haslam D, Tsodikov A, Hammond E, Seaman J, Holden J, et al. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56:922–8.
7. Hambek M, Solbach C, Schnuerch HG, Roller M, Stegmueller M, Sterner-Kock A, et al. Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy. Cancer Res. 2001;61:1045–9.
8. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 2007;98:621–8.
9. Nakagawa M, Nabeshima K, Asano S, Hamasaki M, Uesugi N, Tani H, et al. Up-regulated expression of ADAM17 in gastrointestinal stromal tumors: coexpression with EGFR and EGFR ligands. Cancer Sci. 2009;100:654–62.
10. Lendeckel U, Kohl J, Arndt M, Carl-McGrath S, Donat H, Röcken C. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol. 2005;131:41–8.
11. Levano KS, Kenny PA. Clarification of the C-terminal proteolytic processing site of human amphiregulin. FEBS Lett. 2012;586:3500–2.
12. Higginbotham JN, Beckler MD, Gephart JD, Franklin JL, Bogatcheva G, Kre-mers G-J, et al. Amphiregulin exosomes increase cancer cell invasion. CurrBiol. 2011;21:779–86.
13. Busser B, Sancey L, Brambilla E, Coll J-L, Hurbin A. The multiple roles of amphiregulin in human cancer. Biochim Biophys Acta. 1816;2011:119–31.
14. Suzuki S, Sato M, Senoo H, Ishikawa K. Direct cell–cell interaction enhances pro-MMP-2 production and activation in co-culture of laryngeal cancer cells and fibroblasts: involvement EMMPRIN MT1-MMP. Exp Cell Res. 2004;293:259–66.
15. Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P, et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 2005;65:3193–9.
16. Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, Sauter G, et al. High incidence of EMMPRIN expression in human tumors. Int J Cancer. 2006;119:1800–10.
17. Tang Y, Kesavan P, Nakada MT, Yan L. Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol Cancer Res. 2004;2:73–80.
18. Mi Z, Oliver T, Guo H, Gao C, Kuo PC. Thrombin-cleaved COOH (-) terminal osteopontin peptide binds with cyclophilin C to CD147 in murine breast cancer cells. Cancer Res. 2007;67:4088–97.
19. Gabison EE, Mourah S, Steinfels E, Yan L, Hoang-Xuan T, Watsky MA, et al. Differential expression of extracellular matrix metalloproteinase inducer (CD147) in normal and ulcerated corneas: role in epithelio-stromal interactions and matrix metalloproteinase induction. Am J Pathol. 2005;166:209–19.
20. Zhong WD, Chen QB, Ye YK, Han ZD, Bi XC, Dai QS, et al. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer. Oncology. 2008;75:230–6.
21. Li Y, Shang P, Qian AR, Wang L, Yang Y, Chen ZN. Inhibitory effects of antisense RNA of HAb18G/CD147 on invasion of hepatocellular carcinomacells in vitro. World J Gastroenterol. 2003;9(10):2174–7.
22. Zhong WD, Chen QB, Ye YK, Han ZD, Bi XC, Dai QS, et al. Extracellular matrix metalloproteinase inducer expression has an impact on survival in human bladder cancer. Cancer Epidemiol. 2010;34:478–82.
23. Piao S, Zhao S, Guo F, Xue J, Yao G, Wei Z, et al. Increased expression of CD147 and MMP-9 is correlated with poor prognosis of salivary duct carcinoma. J Cancer Res Clin Oncol. 2012;138:627–35.
24. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52–67.
25. Sheu BC, Lien HC, Ho HN, Lin HH, Chow SN, Huang SC, et al. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res. 2003;63:6537–42.
26. Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 1995;55:434–9.
27. Van der Jagt MF, Wobbes T, Strobbe LJ, Sweep FC, Span PN. Metalloproteinases and their regulators in colorectal cancer. J Surg Oncol. 2010;101:259–69.
28. Pinheiro C, Longatto-Filho A, Pereira SM, Etlinger D, Moreira MA, Jubé LF, et al. Monocarboxylate transporters 1 and 4 are associated with CD147 in cervical carcinoma. Dis Markers. 2009;26:97–103.
29. Ju XZ, Yang JM, Zhou XY, Li ZT, Wu XH. EMMPRIN expression as a prognostic factor in radiotherapy of cervical cancer. Clin Cancer Res. 2008;14:494–501.
30. Boye K, Nesland JM, Sandstad B, Haugland Haugen M, Mælandsmo GM, et al. EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer. Br J Cancer. 2012;107:667–74.
31. Murphy G. The ADAMs: signalling scissors in the tumour micro-environment. Nat Rev Cancer. 2008;8:929–41.
32. Lin P, Sun X, Feng T, Zou H, Jiang Y, Liu Z, et al. ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathway. Mol Cell Biochem. 2012;359:235–43.
33. Tanaka Y, Miyamoto S, Suzuki SO, Oki E, Yagi H, Sonoda K, et al. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res. 2005;11:4783–92.
34. Reddy KB, Krueger JS, Kondapaka SB, Diglio CA. Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells. Int J Cancer. 1999;82:268–73.
35. Price DJ, Avraham S, Feuerstein J, Fu Y, Avraham HK. The invasive phenotype in HMT-3522 cells requires increased EGF receptor signaling through both PI 3-kinase and ERK 1, 2 pathways. Cell Commun Adhes. 2002;9:87–102.
36. Xu Q, Ohara N, Liu J, Amano M, Sitruk-Ware R, Yoshida S, et al. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod. 2008;14:181–91.
37. Yu W, Liu J, Xiong X, Ai Y, Wang H. Expression of MMP9 and CD147 in invasive squamous cell carcinoma of the uterine cervix and their implication. Pathol Res Pract. 2009;205:709–15.
38. Li Y, Wu T, Zhang B, Yao Y, Yin G. Matrix metalloproteinase-9 is a prognostic marker for patients with cervical cancer. Med Oncol. 2012;29:3394–9.
39. Xu P, Derynck R. Direct activation of TACE-mediated ectodomain shedding by p38 MAP kinase regulates EGF receptor-dependent cell proliferation. Mol Cell. 2010;37:551–66.
40. Sternlicht MD, Sunnarborg SW. The ADAM17-amphiregulin-EGFR axis in mammary development and cancer. J Mammary Gland Biol Neoplasia. 2008;13:181–94.
41. Sisto M1, Lisi S, D'Amore M, Lofrumento DD. The metalloproteinase ADAM17 and the epidermal growth factor receptor (EGFR) signaling drive the inflammatory epithelial response in Sjögren's syndrome. Clin Exp Med. 2014 Mar 25.
42. Xiao LJ, Lin P, Lin F, Liu X, Qin W, Zou HF, et al. ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion. Int J Oncol. 2012;40:1714–24.
43. Jin JS, Wu CY, Lin YF, Wang JY, Yu CP, Sheu LF, et al. Higher expression of epidermal growth factor receptor is associated with extracellular matrixmetalloprotease inducer in colorectal adenocarcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters. Dis Markers. 2006;22:309–16.
44. Menashi S, Serova M, Ma L, Vignot S, Mourah S, Calvo F. Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells. Cancer Res. 2003;63:7575–80.